Business
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearanceDuration of effect lasted approximately 3 monthsNo potential
About this update from Dermata Therapeutics, Inc.
[{"type":"text","content":"Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearanceDuration of effect lasted approximately 3 monthsNo potential distant spread of toxin observedSAN DIEGO, CA / ACCESSWIRE / November 19, 2021 / Dermata Therapeutics, Inc. (\"Dermata,\" or the \"Company\") (NASDAQ:DRMA), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today announced positive efficacy and safety data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic skin conditions. This data was presented at The American Society for Dermatologic Surgery 2021 Annual Meeting held today through November 21, 2021.Dermata will be hosting a virtual investor event via live webcast later today at 4:30 pm ET. The live webcast may be accessed via the \"Investors\" section of Dermata's website or by clicking the following link.\"We are excited to present the positive results from this proof of concept study of DMT410 showing our product candidate's ability to achieve topical administration of OnabotulinumtoxinA. During the trial, we saw results across multiple aesthetic endpoints that indicate DMT410's ability to provide targeted topical delivery of OnabotulinumtoxinA to the dermis,\" stated Christopher Nardo, Ph.D., Dermata's Senior Vice President of Development. \"Patients demonstrated improvements in skin quality endpoints, such as brightness, luminosity, and reduction in pore size. Since we did not expect OnabotuliniumtoxinA to penetrate into the muscle, we saw minimal effect on the upper facial lines typically treated with injections of OnabotulinumtoxinA. Based on these data we believe that most of the toxin remained in the dermis limiting potential distant spread of toxin and its side effects.\"DMT410 Phase 1b Aesthetic Study DesignThe Phase 1b proof of concept study was an open-label, single-center study of 10 female patients receiving one treatment of DMT410, which consists of one topical application of Spongilla powder followed by one topical application of 64 units of OnabotulinumtoxinA (BOTOX®) to the upper face. Patients were observed at 4 weeks, 8 weeks, 12 weeks, and 16 weeks to collect safety and efficacy data and track duration of effect.The endpoints of the study included reduction in pore size, improvements in the Glo...